The Department for Energy Security and Net Zero (DESNZ) has published a regulatory study examining the UK framework governing the supply of medical radioisotopes. Produced under the Medical Radionuclide Innovation Programme (MRIP), the report aims to develop an understanding of the roles and requirements of the radiological and civil nuclear safety regulatory bodies within the radiopharmaceutical supply chain. The study was written by the key regulators: Environment Agency (EA), Office for Nuclear Regulation (ONR), Health and Safety Executive (HSE), Natural Resources Wales (NRW), Scottish Environment Protection Agency (SEPA) and Northern Ireland Environment Agency (NIEA). It analyses how responsibilities are distributed across environmental, health and safety and nuclear regulators, and how requirements vary depending on whether activities take place on a nuclear licensed site and the nature of the radioactive materials involved. The regulators conclude that the existing framework is broadly suitable to support current and future medical radionuclide production, including emerging technologies such as particle accelerators, research reactors and extraction from legacy waste, but identify areas requiring further consideration, including the interface between ONR and HSE in determining licensing requirements, the implications of the Radiation (Emergency Preparedness and Public Information) Regulations 2019, SI 2019/703 (REPPIR 2019), and the impact of novel radionuclides on waste management and environmental permitting.